

**Date:** January 9, 2025

To,  
Sr. General Manager  
Listing Department  
**BSE Limited**  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai – 400001

**BSE Scrip Code: 544319**

To,  
Sr. General Manager  
Listing Department  
**National Stock Exchange of India Limited**  
Exchange Plaza, C-1, Block G  
Bandra Kurla Complex  
Bandra (E), Mumbai – 400 051

**NSE Symbol: SENORES**

Dear Sir/Madam,

**Sub.: Media Release – “Senores Pharmaceuticals receives ANDA approval for marketing Metoprolol Tartrate and Hydrochlorothiazide Tablet USP, 50 mg/25 mg and 100 mg/25 mg”**

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith a Media Release issued by Senores Pharmaceuticals Limited on the captioned subject, the content of which is self-explanatory.

This is for information of the Exchanges and the Members.

You are requested to take the same on record.

Thanking you.

**For Senores Pharmaceuticals Limited**

**Vinay Kumar Mishra**  
Company Secretary and Compliance Officer  
ICSI Membership No.: F11464

**Senores Pharmaceuticals Limited**

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,  
Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

P: +91 79 2999 9857 | E: [info@senorespharma.com](mailto:info@senorespharma.com)

W: [www.senorespharma.com](http://www.senorespharma.com) | CIN No.: U24290GJ2017PLC100263

## **Senores Pharmaceuticals receives ANDA approval for marketing Metoprolol Tartrate and Hydrochlorothiazide Tablet USP, 50 mg/25 mg and 100 mg/25 mg**

**Ahmedabad, India, 9 January, 2025:** Senores Pharmaceuticals Limited (including its subsidiaries/affiliates, hereafter referred to as “Senores”) has received final approval from the United States Food and Drug Administration (USFDA) for marketing Metoprolol Tartrate and Hydrochlorothiazide Tablet USP, 50 mg/25 mg and 100 mg/25 mg.

Metoprolol Tartrate and Hydrochlorothiazide Tablet is the combination tablet of metoprolol tartrate, a beta adrenoceptor blocker and hydrochlorothiazide (HCTZ), a thiazide diuretic, indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.

According to IQVIA™ and Symphony sales data for the 12-month period ending November 2024, the Metoprolol Tartrate and Hydrochlorothiazide Tablet USP, 50 mg/25 mg and 100 mg/25 mg market achieved annual sales of approximately \$ 6 million and \$ 10 million respectively.

Senores' current portfolio includes 24 ANDA products that are permitted for distribution in the USA. In addition to these internal filings, Senores is actively seeking external development collaborations to augment and accelerate the growth of its existing pipeline and portfolio.

“We have been relentlessly working in enhancing our product portfolio, which includes a wide range of specialty and complex pharmaceutical products across various therapeutic areas in regulated markets, particularly in the US. Metoprolol Tartrate and Hydrochlorothiazide are specialized formulations with limited competition in the US, providing us an opportunity to capture a higher market share in this region.” **stated Swapnil Shah, Managing Director, Senores Pharmaceuticals Limited.**

**About Senores Pharmaceuticals Limited:**

Senores Pharmaceuticals Limited is global research driven pharmaceutical company engaged in developing and manufacturing specialty, niche and complex products for Regulated and Emerging Markets.

Senores Pharmaceuticals, Inc., based in Georgia, USA, is a wholly owned subsidiary of Senores Pharmaceuticals Limited and one of the fastest-growing pharmaceutical companies in the USA.

**Safe Harbor:**

This document may contain forward-looking statements about Senores Pharmaceuticals Limited and its Subsidiaries, which are based on the beliefs, opinions, and expectations of the company's management as the date of this Investor release and the companies do not assume any obligation to update their forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. These statements are not the guarantees of future performance and involve risks and uncertainties that are difficult to predict. Consequently, readers should not place any undue reliance on such forward-looking statements.

**For more information, contact:**

---

**Company: Senores Pharmaceuticals Ltd.**

**For Media Inquiries, please contact:  
Corporate Communications Department**

Phone: [+91 79 29999857](tel:+917929999857)

**Investor Relations: Strategic Growth Advisors**

**Mr. Sagar Shroff / Mr. Tanay Shah**

M: +91 98205 19303 / +91 98333 91899

E-mail: [sagar.shroff@sgapl.net](mailto:sagar.shroff@sgapl.net) / [tanay.shah@sgapl.net](mailto:tanay.shah@sgapl.net)

---